Company news

Amplia Therapeutics Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Positive ACCENT Trial Topline Data Released

August 5, 2025

Capital Raising Presentation

July 23, 2025

Amplia announces A$25m Placement and Launches A$2.5m SPP

July 23, 2025

Second Complete Response in ACCENT Pancreatic Cancer Trial

June 18, 2025

Pathological complete response recorded in patient from ACCENT cancer trial

June 16, 2025

Pathological Complete Response in Pancreatic Cancer Trial

June 15, 2025

Preliminary Final Report and Annual Report YE 31 March 2025

May 30, 2025

ACCENT Trial Achieves Superiority over Chemotherapy Alone

May 14, 2025

Completion of Recruitment of ACCENT Trial

January 30, 2025

Security Class Reinstatement to Quotation - ATXOA

December 23, 2024

App 4D and Financial Report Half Year ended 30 Sep 2024

November 27, 2024

Security Class Suspension from Quotation

November 24, 2024

Amplia Successfully Completes Institutional Offer

October 31, 2024

Capital Raise Presentation

October 30, 2024

Amplia to Raise up to $13m for ACCENT and US Trials

October 30, 2024

Interim Data From Accent Pancreatic Cancer Trial

October 30, 2024

Sixth Confirmed Response in Pancreatic Cancer Trial

September 22, 2024

FDA Fast Track Designation for Narmafotinib

September 19, 2024

Fifth Confirmed Response in ACCENT Trial

August 20, 2024

Amplia Receives R&D Tax Rebate Totalling $3.2 Million

August 11, 2024

Granting of Key Patent in Europe and Japan

August 7, 2024

Additional Patient Response in Pancreatic Cancer Trial

August 5, 2024

Sustained Reduction in Tumour Size Seen In Pancreatic Trial

July 25, 2024

First 26 Patients recruited in Phase 2A ACCENT Trial

July 3, 2024

Preliminary Final Report and Annual Report YE 31 March 2024

May 30, 2024

$4.27m Offer Successfully Completed and ACCENT Trial Update

May 14, 2024

Rights Issue Investor Slide Deck

April 16, 2024

Fully Underwritten 2 for 5 Entitlement Offer to raise $4.27

April 16, 2024

Update on ACCENT Trial in Pancreatic Cancer

March 26, 2024

FDA Clearance Amplia's IND for Pancreatic Cancer Trial in US

January 17, 2024

Amplia Reports First Patient Dosing In Phase 2a Accent Trial

January 16, 2024

Approval to Initiate Phase2 Pancreatic Cancer Trial in Korea

December 3, 2023

Appendix 4D and Financial Report Half Year ended 30 Sep 23

November 20, 2023

Promising Clinical Data 1b ACCENT Trial in Pancreatic Cancer

October 29, 2023

Amplia Receives R&D Tax Rebate Totalling $ 2.4 Million

October 18, 2023

AACR Ovarian Cancer Conference Presentation

October 8, 2023

ATX Quarterly Activities and Cashflow Reports - June 23 Qtr

July 30, 2023

Annual Report to Shareholders

May 30, 2023

AMP945 and FOLFIRINOX active in model of Pancreatic Cancer

May 28, 2023

Grant to collaborate with CSIRO Supplementary Announcement

May 23, 2023

Amplia receives grant to collaborate with CSIRO

May 21, 2023

ACCENT Trial Recruitment Progress

May 9, 2023

Quarterly Activities and Cashflow Reports - March 23 Qtr

April 26, 2023

First Patient Recruited to Cohort 3 of ACCENT Trial

April 18, 2023

Dose Escalation Approved in ACCENT Clinical Trial of AMP945

April 11, 2023

First Patient Recruited to Cohort 2 of Accent Trial

February 1, 2023

Quarterly Activities and Cashflow Reports - December 2022

January 29, 2023

Letter to Shareholders End of Year Summary and 2023 Plans

December 19, 2022

Appendix 4D and Financial Report Half Year ended 30 Sep 22

November 17, 2022

Amplia Appoints Dr Christopher Burns CEO & Managing Director

November 6, 2022

← Newer news releases · Older news releases →

Decks

The 5 newest of 37 decks. Every deck is listed under its year.